Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 May 2017
At a glance
- Drugs Liraglutide (Primary)
- Indications Nutritional and metabolic diseases; Obesity
- Focus Therapeutic Use
- Acronyms SCALE™ IBT
- Sponsors Novo Nordisk
- 05 May 2017 Planned End Date changed from 22 Jun 2018 to 21 Jun 2018.
- 05 May 2017 Planned primary completion date changed from 23 May 2018 to 22 May 2018.
- 05 May 2017 Status changed from recruiting to active, no longer recruiting.